StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

Investment analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Down 6.4 %

NASDAQ:EVGN opened at $1.46 on Thursday. The company has a fifty day moving average of $1.57 and a 200 day moving average of $2.50. Evogene has a 52 week low of $1.20 and a 52 week high of $10.40. The firm has a market capitalization of $7.84 million, a P/E ratio of -0.33 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) EPS for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.